These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7201820)

  • 21. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL
    Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing activity onset time and efficacy for clinically effective antidepressant and antimanic drugs in animal models based on dominant-submissive relationships.
    Malatynska E; Pinhasov A; Creighton CJ; Crooke JJ; Reitz AB; Brenneman DE; Lubomirski MS
    Neurosci Biobehav Rev; 2007; 31(6):904-19. PubMed ID: 17597209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Finding the effective dose of diuretics in man (author's transl)].
    Rupp W
    Arzneimittelforschung; 1977 Feb; 27(2A):289-95. PubMed ID: 577179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria for selection of physiologically active substances (pharmacometry under screening conditions).
    Dmitrieva NV; Kaplun AB; Lobanov VI; Nizhnii SV; Piruzyan LA
    Biol Bull Acad Sci USSR; 1979; 6(6):780-7. PubMed ID: 552856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis.
    Bolton C
    Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harnessing preclinical mouse models to inform human clinical cancer trials.
    Gutmann DH; Hunter-Schaedle K; Shannon KM
    J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction of an information-theoretic method to predict recovery rates of active compounds for Bayesian in silico screening: theory and screening trials.
    Vogt M; Bajorath J
    J Chem Inf Model; 2007; 47(2):337-41. PubMed ID: 17302401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries.
    Cruz-Monteagudo M; Borges F; Cordeiro MN; Cagide Fajin JL; Morell C; Ruiz RM; Cañizares-Carmenate Y; Dominguez ER
    J Comb Chem; 2008; 10(6):897-913. PubMed ID: 18855460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling for pharmaceutical toxicology screening.
    Bugelski PJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):79-89. PubMed ID: 11865676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis?
    Pires NM; Jukema JW; Daemen MJ; Quax PH
    Vascul Pharmacol; 2006 May; 44(5):257-64. PubMed ID: 16527546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments.
    Van Rompay KK
    AIDS Rev; 2005; 7(2):67-83. PubMed ID: 16092501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies.
    Dixit R; Boelsterli UA
    Drug Discov Today; 2007 Apr; 12(7-8):336-42. PubMed ID: 17395094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The screening toolbox of bioactive substances from natural products: a review.
    Wang B; Deng J; Gao Y; Zhu L; He R; Xu Y
    Fitoterapia; 2011 Dec; 82(8):1141-51. PubMed ID: 21867747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,026 experimental treatments in acute stroke.
    O'Collins VE; Macleod MR; Donnan GA; Horky LL; van der Worp BH; Howells DW
    Ann Neurol; 2006 Mar; 59(3):467-77. PubMed ID: 16453316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical testing for teratogenicity and developmental toxicity: methods and limitations.
    Barrow PC
    Therapie; 2002; 57(2):109-14. PubMed ID: 12185956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs.
    Castel-Branco MM; Alves GL; Figueiredo IV; Falcão AC; Caramona MM
    Methods Find Exp Clin Pharmacol; 2009 Mar; 31(2):101-6. PubMed ID: 19455265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing throughput in lead optimization in vivo toxicity screens.
    Meador V; Jordan W; Zimmermann J
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):72-8. PubMed ID: 11865675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Problems in dermato-toxicologic checking programs (author's transl)].
    Heise H; Schiller F; Ziegler V; Zschunke E
    Dermatol Monatsschr; 1979 Jun; 165(6):412-7. PubMed ID: 499626
    [No Abstract]   [Full Text] [Related]  

  • 40. Double-step procedure screening for modeling reactive (exogenous) depression in rats.
    Barbakadze M; Chkhetiani M; Nebieridze N; Mariamidze M; Koreli A
    Georgian Med News; 2009 May; (170):101-4. PubMed ID: 19556653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.